Eli Lilly Stock Is Rising Tuesday: What's Going On?
Eli Lilly Stock Is Rising Tuesday: What's Going On?
The move is part of the Biden-Harris Administration's national strategy on Hunger, Nutrition and Health focused on ending hunger and reducing diet-related diseases such as obesity. Eli Lilly And Co (NYSE:LLY) shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to expand coverage of anti-obesity medications for Americans with Medicare and Medicaid.
礼来（纽交所: LLY）股价周二有所上涨，此前拜登-哈里斯政府提议一项新规定，扩大对拥有医疗保险和医疗补助的美国人提供抗肥胖药物的覆盖范围。
What Happened: The government has proposed a new rule to expand access to medications for obesity. In a statement released Monday, the Biden-Harris Administration said Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95% for some enrollees. Approximately 4 million Medicaid enrollees would also gain access to these medications.
事件经过: 政府提议一项新规定，扩大肥胖药物的使用范围。拜登-哈里斯政府周一发布的一份声明中表示，医疗保险将使这些处方药对一些参保人员的自付费用降低至95%。大约400万医疗补助参保人员也将获得使用这些药物的权限。
"The President is proud of the fact that the Inflation Reduction Act allows Medicare to negotiate down the price of drugs, a tool that will help Medicare lower the cost of some of the most expensive medications in the program. That power to negotiate drug prices is critical because Americans pay two to three times more than people in other countries for their prescription drugs," the White House said in a statement.
“总统为《通胀削减法案》允许医疗保险就药品价格进行议价感到自豪，这一工具将帮助医疗保险降低节目中一些最昂贵药物的成本。议价药品价格的能力至关重要，因为美国人为他们的处方药付出的费用是其他国家人数的两到三倍高。” 白宫在一份声明中表示。
The move is part of the Biden-Harris Administration's national strategy on Hunger, Nutrition and Health focused on ending hunger and reducing diet-related diseases such as obesity.
此举是拜登-哈里斯政府关于结束饥饿、减少肥胖等与饮食有关疾病的国家战略的一部分。
The anti-obesity drug market has expanded in recent years with FDA approval for a new class of drugs like Eli Lilly's Zepbound, which can cost close to $1,000 per month for those paying out-of-pocket.
最近几年，随着FDA批准了类似礼来的 Zepbound 这类新药物，抗肥胖药物市场有所扩大，对那些自费购买的人来说，这些药物的成本可能接近每月1000美元。
One of the main parts of the Biden-Harris Administration's strategy involves recognizing the opportunity within Medicare and Medicaid to support access to nutritious foods, obesity counseling and other nutrition-related services.
拜登-哈里斯政府战略的主要部分之一是认识到在医疗保险和医疗补助中支持获得营养食品、肥胖咨询和其他营养相关服务的机会。
"Obesity is a multi-faceted disease and we need to work on all levels from prevention to treatment to address this persistent challenge," the White House said.
“肥胖是一个多方面的疾病，我们需要在预防、治疗等各个层面上努力应对这一持续挑战，” 白宫表示。
Eli Lilly's Zepbound generated $1.26 billion in sales for the company in its most recent quarter. Eli Lilly said Mounjaro and Zepbound sales in the third quarter were negatively impacted by inventory decreases in the wholesaler channel.
礼来的 Zepbound 在公司最近一个季度实现了12.6亿美元的销售额。礼来表示，Mounjaro 和 Zepbound 的销售在第三季度受到批发商渠道库存减少的影响。
LLY Price Action: Eli Lilly shares were up 3.58% at $782.00 at the time of publication Tuesday, according to Benzinga Pro.
礼来股价表现：根据Benzinga Pro的数据，在周二发布时，礼来股价上涨了3.58%，报收782.00美元。
Photo: Shutterstock.
照片：shutterstock。
